CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC скачать в хорошем качестве

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC

Effective treatment options for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) is an unmet need. Alex Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, discusses the findings of a trial of amivantamab, an EGFR-MET bispecific antibody shown to have efficacy in this exon20ins cohort. The CHRYSALIS study (NCT02609776) enrolled over 80 patients with advanced exon20ins NSCLC in the dose-expansion phase following determination of 1050 mg as the recommended Phase II dose in the dose-escalation cohort. An overall response rate of 36% was achieved and the clinical benefit rate was 73%. Amivantamab showed a good safety profile, with low rates of dose reductions and discontinuation. The therapy has received FDA breakthrough therapy designation in this setting and is under continued investigation. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.